HLB SCIENCE Inc.
Develops drugs and diagnostics for infectious, immune, and Alzheimer's diseases.
343090 | KO
Overview
Corporate Details
- ISIN(s):
- KR7343090007
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 송파구 법원로 128씨동 1314호, 서울특별시
Description
HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-25 00:00 |
전환가액의조정(제2회차 CB)
|
Korean | 9.8 KB | ||
| 2023-01-09 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득(제3회차)
|
Korean | 8.5 KB | ||
| 2023-01-09 00:00 |
전환가액의조정(제3회차)
|
Korean | 10.0 KB | ||
| 2022-12-29 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 85.5 KB | ||
| 2022-12-23 00:00 |
[기재정정]감사보고서 (2019.12)
|
Korean | 240.5 KB | ||
| 2022-12-23 00:00 |
[기재정정]사업보고서 (2019.12)
|
Korean | 240.5 KB | ||
| 2022-12-23 00:00 |
[기재정정]사업보고서 (2020.12)
|
Korean | 307.0 KB | ||
| 2022-12-23 00:00 |
[기재정정]사업보고서 (2021.12)
|
Korean | 646.1 KB | ||
| 2022-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2022-11-25 00:00 |
기업설명회(IR)개최결과
|
Korean | 6.5 KB | ||
| 2022-11-09 00:00 |
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2022-10-24 00:00 |
전환가액의조정(제2회차 CB)
|
Korean | 9.7 KB | ||
| 2022-10-07 00:00 |
전환가액의조정(제3회차 CB)
|
Korean | 9.8 KB | ||
| 2022-10-07 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득(제3회차 CB)
|
Korean | 8.5 KB | ||
| 2022-07-27 00:00 |
임상시험단계진입ㆍ종료(자율공시)(패혈증 / 그람음성 슈퍼박테리아 감염증 신약의 임상 1상 시험계획(IND) 승인)
|
Korean | 7.9 KB |
Automate Your Workflow. Get a real-time feed of all HLB SCIENCE Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HLB SCIENCE Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HLB SCIENCE Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
